![Satya Kuchimanchi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Satya Kuchimanchi
Directeur Technique/Scientifique/R&D chez
CAMP4 THERAPEUTICS CORPORATION
Profil
Satya Kuchimanchi currently works at CAMP4 Therapeutics Corp., as Senior Vice President-Technical Operations from 2022.
Dr. Kuchimanchi also formerly worked at Alnylam Pharmaceuticals, Inc., as Director-Process Development from 2008 to 2020 and Triplet Therapeutics, Inc., as Vice President-CMC from 2020 to 2022.
Dr. Kuchimanchi received his doctorate degree from Osmania University.
Postes actifs de Satya Kuchimanchi
| Sociétés | Poste | Début |
|---|---|---|
| CAMP4 THERAPEUTICS CORPORATION | Directeur Technique/Scientifique/R&D | 01/06/2022 |
Anciens postes connus de Satya Kuchimanchi
| Sociétés | Poste | Fin |
|---|---|---|
Triplet Therapeutics, Inc.
 Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | Corporate Officer/Principal | 01/05/2022 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2020 |
Formation de Satya Kuchimanchi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Osmania University
 Osmania University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | Health Services |
